Prophylaxis of atrial fibrillation (AF)-related cardioembolism in oncology is often challenging [1]. The CHA2DS2-VASc score performs differently according to the presence or absence of cancer, with more thromboembolic and bleeding events occurring in subjects with than without malignancy and a CHA2DS2-VASc score <2 [2]. INR values are often out of the therapeutic range in oncological patients receiving vitamin K antagonist (VKA), and the pharmacokinetics and pharmacodynamics of direct oral anticoagulants (DOAC) may be significantly affected by antineoplastic therapies [1].
